Bristol Myers Squibb will present new data from its broad oncology portfolio and research pipeline at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. The company will share findings from more than 50 studies, including company-sponsored, investigator-initiated, and collaborative trials, covering over 10 cancer types. 

“This year’s ESMO meeting underscores the significant scientific progress we are making across our oncology portfolio,” said Anne Kerber, Senior Vice President, Head of Development, Hematology, Oncology and Cell Therapy at Bristol Myers Squibb.

“The data we are presenting reflect our deep commitment to advancing novel therapeutic mechanisms and treatment modalities that address diverse tumor types and hard-to-treat cancers. We remain focused on delivering the next generation of transformative medicines to patients around the world.” 

Among the presentations are results from a global Phase 1 study of izalontamab brengitecan, a potential first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with metastatic non–small cell lung cancer (NSCLC) and other solid tumors. Findings from this study supported the U.S. FDA’s Breakthrough Therapy designation for iza-bren in previously treated advanced EGFR-mutated NSCLC. 

Bristol Myers Squibb will also present late-breaking updates from the CheckMate -8HW trial, evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo monotherapy or investigator’s choice of chemotherapy in patients with MSI-H/dMMR metastatic colorectal cancer. The data will include updated progression-free survival and the first disclosure of overall survival results. 

Additional highlights include five-year follow-up data from the CheckMate -274 study evaluating adjuvant Opdivo in patients with high-risk muscle-invasive urothelial carcinoma following radical resection, as well as the nine-year final analysis from CheckMate -238, comparing adjuvant Opdivo versus Yervoy in resected advanced melanoma.